Portal de Periódicos da CAPES

Pharmacokinetic Considerations for New Targeted Therapies

2008; Wiley; Volume: 85; Issue: 2 Linguagem: Inglês

10.1038/clpt.2008.242

1532-6535

Sharyn D. Baker, Shuiying Hu,

Chronic Lymphocytic Leukemia Research

Targeted therapies are increasingly being incorporated into standard treatment regimens for cancer. Tyrosine kinase inhibitors represent one class of targeted agents, and in recent years eight of these drugs have received approval for the treatment of cancer. Although tyrosine kinase inhibitors hold promise of being more effective and less toxic to normal cells than conventional cytotoxic chemotherapy, they are associated with various adverse effects, sometimes severe, as well as wide pharmacokinetic variability. Therefore, a "therapeutic window" may exist for these agents. Clinical Pharmacology & Therapeutics (2009); 85, 2, 208–211 doi:10.1038/clpt.2008.242